Literature DB >> 15864117

Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Sharon K Krueger1, Lisbeth K Siddens, Marilyn C Henderson, Eric A Andreasen, Robert L Tanguay, Clifford B Pereira, Erwin T Cabacungan, Ronald N Hines, Kristin G Ardlie, David E Williams.   

Abstract

OBJECTIVES: Previous work defined two flavin-containing monooxygenase 2 (FMO2) alleles. The major allele, FMO2*2 (g.23,238C>T), encodes truncated inactive protein (p.X472) whereas the minor allele, FMO2*1, present in African- and Hispanic-American populations, encodes active protein (p.Q472). Recently, four common (27 to 51% incidence) FMO2 single nucleotide polymorphisms (SNPs) were detected in African-Americans (N=50); they encode the following protein variants: p.71Ddup, p.V113fs, p.S195L and p.N413 K. Our objectives were to: (1) determine the incidence of these SNPs in 29 Hispanic individuals previously genotyped as g.23,238C (p.Q472) and 124 previously genotyped as homozygous g.23,238 T (p.X472); (2) determine FMO2 haplotypes in this population; and (3) assess the functional impact of SNPs in expressed proteins.
METHODS: SNPs were detected via allele-specific oligonucleotide amplification coupled with real-time or electrophoretic product detection, or single strand conformation polymorphism.
RESULTS: The g.7,700_7,702dupGAC SNP (p.71Ddup) was absent. The remaining SNPs were present but, except for g.13,732C>T (p.S195L), were less common in the current Hispanic study population versus the previously described African-Americans. Only expressed p.N413 K was as active as p.Q472, as determined by methimazole- and ethylenethiourea-dependent oxidation. Haplotype determination demonstrated that the g.10,951delG (p.V113fs), g.13,732C>T (p.S195L) and g.22,060T>G (p.N413 K) variants segregated with g.23,238C>T (p.X472).
CONCLUSIONS: SNPs would not alter FMO2 activity in individuals possessing at least one FMO2*1 allele. It is likely that these SNPs will segregate similarly in African-American populations. Therefore, estimates that 26% of African-Americans and 2-7% of Hispanic-Americans have at least one FMO2*1 allele should closely reflect the percentages producing active FMO2 protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864117      PMCID: PMC1351039          DOI: 10.1097/01213011-200504000-00008

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  33 in total

1.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

Review 2.  The role of flavin-containing monooxygenases in drug metabolism and development.

Authors:  John R Cashman
Journal:  Curr Opin Drug Discov Devel       Date:  2003-07

3.  The New York Cancer Project: rationale, organization, design, and baseline characteristics.

Authors:  Maria K Mitchell; Peter K Gregersen; Stephen Johnson; Ramon Parsons; David Vlahov
Journal:  J Urban Health       Date:  2004-06       Impact factor: 3.671

4.  Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters.

Authors:  Diana Hernandez; Azara Janmohamed; Pritpal Chandan; Ian R Phillips; Elizabeth A Shephard
Journal:  Pharmacogenetics       Date:  2004-02

5.  Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione.

Authors:  Marilyn C Henderson; Sharon K Krueger; Jan F Stevens; David E Williams
Journal:  Chem Res Toxicol       Date:  2004-05       Impact factor: 3.739

6.  Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Authors:  Ronald N Hines; Kathleen A Hopp; Jose Franco; Kia Saeian; Frank P Begun
Journal:  Mol Pharmacol       Date:  2002-08       Impact factor: 4.436

7.  Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.

Authors:  Yi-Min Zheng; Kirk R Henne; Patrick Charmley; Richard B Kim; D Gail McCarver; Erwin T Cabacungan; Ronald N Hines; Allan E Rettie
Journal:  Toxicol Appl Pharmacol       Date:  2003-01-15       Impact factor: 4.219

Review 8.  Genetic polymorphisms of flavin-containing monooxygenase (FMO).

Authors:  Sharon K Krueger; David E Williams; Mei-Fei Yueh; Sarah R Martin; Ronald N Hines; Judy L Raucy; Colin T Dolphin; Elizabeth A Shephard; Ian R Phillips
Journal:  Drug Metab Rev       Date:  2002-08       Impact factor: 4.518

Review 9.  An overview of the mechanism, substrate specificities, and structure of FMOs.

Authors:  Daniel M Ziegler
Journal:  Drug Metab Rev       Date:  2002-08       Impact factor: 4.518

10.  Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.

Authors:  Bjarte Furnes; Jinong Feng; Steve S Sommer; Daniel Schlenk
Journal:  Drug Metab Dispos       Date:  2003-02       Impact factor: 3.922

View more
  9 in total

1.  Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide.

Authors:  Lisbeth K Siddens; Sharon K Krueger; Marilyn C Henderson; David E Williams
Journal:  Biochem Pharmacol       Date:  2014-02-19       Impact factor: 5.858

Review 2.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Authors:  Sharon K Krueger; Marilyn C Henderson; Lisbeth K Siddens; Jonathan E VanDyke; Abby D Benninghoff; P Andrew Karplus; Bjarte Furnes; Daniel Schlenk; David E Williams
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

5.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

6.  Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms.

Authors:  Lisbeth K Siddens; Marilyn C Henderson; Jonathan E Vandyke; David E Williams; Sharon K Krueger
Journal:  Biochem Pharmacol       Date:  2007-09-08       Impact factor: 5.858

7.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

8.  An ancestral human genetic variant linked to an ancient disease: A novel association of FMO2 polymorphisms with tuberculosis (TB) in Ethiopian populations provides new insight into the differential ethno-geographic distribution of FMO2*1.

Authors:  Ephrem Mekonnen; Endashaw Bekele
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 9.  Properties and Mechanisms of Flavin-Dependent Monooxygenases and Their Applications in Natural Product Synthesis.

Authors:  Yaming Deng; Quan Zhou; Yuzhou Wu; Xi Chen; Fangrui Zhong
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.